Flamel Technologies Sa (FLML): Sandra L Hatten , Sr. VP, Quality & Reg Affairs of Flamel Technologies Sa purchased 3,000 shares on Mar 18, 2016. The Insider buying transaction was disclosed on Mar 21, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.01 per share for a total value of $33,030.00.
Company has been under the radar of several Street Analysts.Flamel Technologies S.A. (ADR) is Reiterated by Laidlaw to Buy while Lowering the Price Target of the company shares to $ 25 from a previous price target of $30 . The Rating was issued on Jan 21, 2016.Flamel Technologies S.A. (ADR) is Reiterated by ROTH Capital to Buy while Lowering the Price Target of the company shares to $ 17.50 from a previous price target of $21 . The Rating was issued on Jan 11, 2016.
Institutional Investors own 75.01% of Flamel Technologies S.A. (ADR) shares.
Shares of Flamel Technologies S.A. (ADR) (FLML) ended Friday, Mar 18, 2016 session in red amid volatile trading. The shares closed down -0.27 points or -2.43% at $10.82 with 6,26,423 shares getting traded. Post opening the session at $11.3, the shares hit an intraday low of $10.635 and an intraday high of $11.3 and the price vacillated in this range throughout the day. The company has a market cap of $435 M and the number of outstanding shares has been calculated to be 4,02,34,506 shares. The 52-week high of Flamel Technologies S.A. (ADR) is $26.09 and the 52-week low is $7.56.
Flamel Technologies SA is a pharmaceutical company. The Companys focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Companys products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR the lead product using the Companys Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate) a non-selective antagonist of Beta 1 Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.